Please login to the form below

Not currently logged in
Email:
Password:

IRX Therapeutics appoints Luba Greenwood to its board

She recently served as venture partner at Colt Ventures

Clinical-stage company IRX Therapeutics has appointed Luba Greenwood to its board of directors.

Her career has seen her gain significant pharmaceutical and biotechnology industry expertise, including building technology companies and providing strategic counsel to corporations.

Mark Leuchtenberger, president and chief executive officer, IRX Therapeutics, said: “Luba is a proven and respected leader in the life science sector.

“She has excelled as an investor, business development professional, lawyer and corporate strategist.”

Her career has spanned leadership roles in venture investing, business development, mergers and acquisitions, law, consulting and operations.

Greenwood most recently served as venture partner at Colt Ventures, and led business development strategy for Pronutria.

Prior to that, she served as senior mergers and acquisitions counsel at Pfizer.

She said: “I look forward to working with the management team as they explore the potential to reduce immune suppression in the tumour microenvironment with IRX-2.”

6th December 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics